Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotropic Hormone

Relapses in multiple sclerosis (MS) are disruptive and frequently disabling for patients, and their treatment is often a challenge to clinicians. Despite progress in the understanding of the pathophysiology of MS and development of new treatments for long-term management of MS, options for treating relapses have not changed substantially over the past few decades. Corticosteroids, a component of the hypothalamic-pituitary-adrenal axis that modulate immune responses and reduce inflammation, are currently the mainstay of relapse treatment. Adrenocorticotropic hormone (ACTH) gel is another treatment option. Although it has long been assumed that the efficacy of ACTH in treating relapses depends on the peptide’s ability to increase endogenous corticosteroid production, evidence from research on the melanocortin system suggests that steroidogenesis may only partly account for ACTH influences. Indeed, the melanocortin peptides [ACTH and α-, β-, γ-melanocyte-stimulating hormones (MSH)] and their receptors (Melanocortin receptors, MCRs) exert multiple actions, including modulation of inflammatory and immune mediator production. MCRs are widely distributed within the central nervous system and in peripheral tissues including immune cells (e.g., macrophages). This suggests that the mechanism of action of ACTH includes not only steroid-mediated indirect effects, but also direct anti-inflammatory and immune-modulating actions via the melanocortin system. An increased understanding of the role of the melanocortin system, particularly ACTH, in the immune and inflammatory processes underlying relapses may help to improve relapse management.

• Publication year

  2013

• Venue

  Frontiers in Neurology

• Publication date

  2013-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fneur.2013.00021PMID 23482896PMCID 3591751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Defining the clinical course of multiple sclerosis

  2014cited by this paper
• Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis.

  2011cited by this paper
• Immunologic aspects of multiple sclerosis.

  2011cited by this paper
• Treatment of Infantile Spasms

  2011cited by this paper
• B cells in spontaneous autoimmune diseases of the central nervous system.

  2011cited by this paper
• Ingested (oral) ACTH inhibits EAE.

  2011cited by this paper
• Evidence-based guideline update: Plasmapheresis in neurologic disorders

  2011cited by this paper
• Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models.

  2011cited by this paper
• Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis

  2011cited by this paper
• A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis

  2011cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Role of the innate immune system in the pathogenesis of multiple sclerosis.

  2010cited by this paper
• Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis.

  2010cited by this paper
• B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunity

  2010cited by this paper
• A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

  2010cited by this paper
• IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS: NEW INSIGHTS AND THERAPEUTIC IMPLICATIONS

  2010influential reference
• Mechanisms underlying inflammation in neurodegeneration.

  2010cited by this paper
• Melanocortin 1 receptor agonists reduce proteinuria.

  2010cited by this paper
• Melanocortin‐4 receptor expression in a vago‐vagal circuitry involved in postprandial functions

  2010influential reference
• ACTH protects against glucocorticoid-induced osteonecrosis of bone

  2010influential reference
• The Melanocortin System in Control of Inflammation

  2010cited by this paper
• Trafficking of immune cells in the central nervous system.

  2010cited by this paper
• Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein

  2010cited by this paper
• T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

  2010cited by this paper
• Spotlight series: pivotal trials through today's knowledge--adrenocorticotrophic hormone.

  2009cited by this paper
• Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.

  2009cited by this paper
• Relapse Management in Multiple Sclerosis

  2009cited by this paper
• Regulation of the Hypothalamic-Pituitary-Adrenal Axis

  2009influential reference
• Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis

  2009cited by this paper
• Spotlight series: pivotal trials through today's knowledge--adrenocorticotrophic hormone.

  2009cited by this paper
• The relation between inflammation and neurodegeneration in multiple sclerosis brains

  2009cited by this paper
• High Dose Oral Steroids Commonly Used to Treat Relapses in Canadian MS Clinics

  2009cited by this paper
• The Interleukin-8 Pathway in Cancer

  2008cited by this paper
• Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis

  2008cited by this paper
• Neuroprotective actions of melanocortins: a therapeutic opportunity.

  2008cited by this paper
• Multiple Sclerosis and Regulatory T Cells

  2008cited by this paper
• Myelin repair: the role of stem and precursor cells in multiple sclerosis

  2008cited by this paper
• NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis.

  2008cited by this paper
• Recommendations Regarding Corticosteroids in the Management of Multiple Sclerosis

  2008cited by this paper
• The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (α-MSH) therapy

  2008cited by this paper
• The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies

  2008cited by this paper
• Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis

  2008cited by this paper
• Behavioral / Systems / Cognitive Presynaptic Melanocortin-4 Receptors on Vagal Afferent Fibers Modulate the Excitability of Rat Nucleus Tractus Solitarius Neurons

  2008cited by this paper
• EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases

  2008cited by this paper
• Immunologic mechanisms of multiple sclerosis.

  2008influential reference
• Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Adrenocorticotropic hormone elevates gene expression for catecholamine biosynthesis in rat superior cervical ganglia and locus coeruleus by an adrenal independent mechanism.

  2008cited by this paper
• Astrocytes in multiple sclerosis: A product of their environment

  2008cited by this paper
• Multiple sclerosis

  2008cited by this paper
• Homogeneity of active demyelinating lesions in established multiple sclerosis

  2008cited by this paper
• Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

  2008cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Functional characterization of two melanocortin (MC) receptors in lamprey showing orthology to the MC1 and MC4 receptor subtypes

  2007cited by this paper
• Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

  2007cited by this paper
• Multiple sclerosis: Is there neurodegeneration independent from inflammation?

  2007cited by this paper
• The blood–brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting

  2007influential reference
• The Immunopathology of Multiple Sclerosis: An Overview

  2007cited by this paper
• The natural history of relapses in multiple sclerosis.

  2007cited by this paper
• Stress and Disease Progression in Multiple Sclerosis and Its Animal Models

  2007cited by this paper
• α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

  2007cited by this paper
• Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

  2006cited by this paper
• Evolution of melanocortin systems in fish.

  2006cited by this paper
• Multiple sclerosis--the plaque and its pathogenesis.

  2006cited by this paper
• Effect of high‐dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation

  2006cited by this paper
• α‐melanocyte‐stimulating hormone down‐regulates CXC receptors through activation of neutrophil elastase

  2006cited by this paper
• Secondary progressive in contrast to relapsing‐remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T‐cell function and FOXP3 expression

  2006cited by this paper
• Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia.

  2006cited by this paper
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.

  2006cited by this paper
• The contribution of demyelination to axonal loss in multiple sclerosis.

  2006cited by this paper
• Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.

  2006influential reference
• The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival.

  2006cited by this paper
• α-Melanocyte-Stimulating Hormone Suppresses Antigen-Induced Lymphocyte Proliferation in Humans Independently of Melanocortin 1 Receptor Gene Status1

  2005cited by this paper
• Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis.

  2005cited by this paper
• Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis

  2005influential reference
• Cortical demyelination and diffuse white matter injury in multiple sclerosis.

  2005cited by this paper
• Quantitative Measurement of the Levels of Melanocortin Receptor Subtype 1, 2, 3 and 5 and Pro‐Opio‐Melanocortin Peptide Gene Expression in Subsets of Human Peripheral Blood Leucocytes

  2005cited by this paper
• Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells.

  2005cited by this paper
• Dopamine and noradrenaline control distinct functions in rodent microglial cells.

  2005cited by this paper
• Hypothalamic-pituitary-adrenocortical axis regulation.

  2005cited by this paper
• The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

  2005cited by this paper
• Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis.

  2005cited by this paper
• The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

  2005influential reference
• The role of stress-response systems for the pathogenesis and progression of MS.

  2005cited by this paper
• Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study

  2005cited by this paper
• Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis

  2004cited by this paper
• Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation

  2004influential reference
• CME Practice Parameter : Medical Treatment of Infantile Spasms

  2004cited by this paper
• Impaired hypothalamus‐pituitary‐adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions

  2004cited by this paper
• Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype

  2004cited by this paper
• Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway.

  2004cited by this paper
• Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors.

  2004cited by this paper
• The melanocortin system in Fugu: determination of POMC/AGRP/MCR gene repertoire and synteny, as well as pharmacology and anatomical distribution of the MCRs.

  2004cited by this paper
• Evidence of Wallerian degeneration in normal appearing white matter in the early stages of relapsing-remitting multiple sclerosis

  2003cited by this paper
• Effect of relapses on development of residual deficit in multiple sclerosis

  2003cited by this paper
• alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways.

  2003cited by this paper
• α-Melanocyte-stimulating Hormone Inhibits Lipopolysaccharide-induced Tumor Necrosis Factor-α Production in Leukocytes by Modulating Protein Kinase A, p38 Kinase, and Nuclear Factor κB Signaling Pathways*

  2003cited by this paper
• Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat

  2003cited by this paper
• The Hypothalamo‐Pituitary‐Adrenal Axis in Multiple Sclerosis

  2003cited by this paper
• α-Melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression

  2003cited by this paper
• Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression.

  2003cited by this paper

• MicroRNA-mediated post-transcriptional regulation in the pathogenesis of multiple sclerosis

  2026cites this paper
• Therapeutic Plasma Exchange in Corticosteroid-Refractory Multiple Sclerosis Relapses: Mechanisms, Efficacy, and Integration into Clinical Practice

  2025cites this paper
• Machine learning in biological research: key algorithms, applications, and future directions

  2025cites this paper
• Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management

  2024cites this paper
• Anti-inflammatory Therapy for Sarcoidosis.

  2023cites this paper
• Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis

  2023cites this paper
• Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids

  2022cites this paper
• Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis

  2022cites this paper
• Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination

  2022cites this paper
• A Simple Computational Approach to Identify Potential Drugs for Multiple Sclerosis and Cognitive Disorders from Expert Curated Resources.

  2022cites this paper
• Pathogenesis and management of multiple sclerosis revisited.

  2022cites this paper
• Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review

  2022cites this paper
• Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update

  2021influential citation
• Headache in multiple sclerosis - pharmacological aspects.

  2021cites this paper
• Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis

  2021cites this paper
• Role of Melanocortins in Inflammation and Other Therapeutic Indications Like Pulmonary Inflammatory, Allergic and Neurological Disorders Like Multiple Sclerosis, Infantile Spasms and Brain Injury-A Systematic Review

  2020cites this paper
• OARRR_A_231667 21..28

  2020cites this paper
• Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis

  2020cites this paper
• Cosyntropin Attenuates Neuroinflammation in a Mouse Model of Traumatic Brain Injury

  2020cites this paper
• Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists

  2020influential citation
• Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records

  2019cites this paper
• Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.

  2019cites this paper
• The Importance of Melanocortin Receptors and Their Agonists in Pulmonary Disease

  2019cites this paper
• Repository corticotropin injection in multiple sclerosis: an update.

  2018cites this paper
• Repository corticotropin for Chronic Pulmonary Sarcoidosis

  2017cites this paper
• CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS

  2017cites this paper
• The efficacy of adrenocorticotropic hormone in a girl with anti-N-methyl-D-aspartate receptor encephalitis.

  2017cites this paper
• Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients—A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness

  2017cites this paper
• Fatigue in Multiple Sclerosis: Is it related to cytokines and hypothalamic-pituitary-adrenal axis?

  2017cites this paper
• A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients.

  2016cites this paper
• Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®

  2016cites this paper
• Fingolimod for Multiple Sclerosis; Mechanism of Action, Safety and Toxicity

  2016influential citation
• Circadian Clocks, Stress, and Immunity

  2016cites this paper
• Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3

  2016cites this paper
• H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes

  2016influential citation
• Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage.

  2015cites this paper
• Treatment of Sarcoidosis

  2015cites this paper
• ACTH gel in the treatment of multiple sclerosis exacerbation: a case study

  2015cites this paper
• Immuntherapien und infektiologische Probleme bei Multipler Sklerose

  2015cites this paper
• Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review

  2015cites this paper
• Role of Adrenocorticotropic Hormone in the Modulation of Pollinosis Induced by Pollen Antigens

  2014cites this paper
• Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis

  2014influential citation
• Glucocorticosteroids: Risk-Benefit Appraisals in Multiple Sclerosis and MS-Associated Optic Neuritis

  2014cites this paper
• Multiple sclerosis treatment and infectious issues: update 2013

  2014cites this paper
• Immunologic Evaluation in the Patients with Infantile Spasm

  2013cites this paper
• Treatment of Sarcoidosis

  2008cites this paper